Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-04-01
Here's how much Ozempic and similar drugs have soared in popularity since 2018
The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.R [...]
2025-03-17
The cost of GLP-1s needs to come way down for benefits to be worth it, study says
While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according t [...]
2025-03-14
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
2025-05-07
Weight Watchers files for bankruptcy amid refocus on GLP-1 drugs
WeightWatchers (WW) announced Tuesday that it is filing for bankruptcy in an attempt to crawl out of more than $1 billion in debt. The news comes as the company is amid a refocus on prescribing weight [...]